Literature DB >> 19915485

Increased matrix metalloproteinase 9 activity in mild cognitive impairment.

Martin A Bruno1, Elliott J Mufson, Joanne Wuu, A Claudio Cuello.   

Abstract

Nerve growth factor (NGF)-dependent cholinergic basal forebrain neurons degenerate during the progression of Alzheimer disease (AD). Elevated proNGF and reduced levels of the TrkA high-affinity NGF receptor occur in prodromal and advanced stages of AD. We recently described a protease cascade responsible for the conversion of proNGF to mature NGF (mNGF) in which matrix metalloproteinase 9 (MMP-9) degrades mNGF in the extracellular space. To determine whether this proteolytic cascade is altered during the progression of AD, we examined human frontal and parietal cortex tissues from aged subjects with a clinical diagnosis of AD, mild cognitive impairment, or no cognitive impairment. The analysis demonstrated greater MMP-9 activity in both AD and mild cognitive impairment compared with no cognitive impairment brain samples (p < 0.01), which supports the notion that a metabolic failure in the NGF-maturation/degradation pathway may be associated with an exacerbated degradation of mNGF in the cerebral cortex in early AD. Moreover, there were inverse correlations between Global Cognitive Score and Mini-Mental State Examination score and MMP-9 activity. These findings suggest that a reduction in mNGF as a consequence of MMP-9-mediated degradation may in part underlie the pathogenesis of cognitive deficits in mild cognitive impairment and AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19915485      PMCID: PMC2810197          DOI: 10.1097/NEN.0b013e3181c22569

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  72 in total

1.  Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes.

Authors:  Suman Deb; J Wenjun Zhang; Paul E Gottschall
Journal:  Brain Res       Date:  2003-04-25       Impact factor: 3.252

2.  A TrkA-to-p75NTR molecular switch activates amyloid beta-peptide generation during aging.

Authors:  Claudio Costantini; Richard Weindruch; Giuliano Della Valle; Luigi Puglielli
Journal:  Biochem J       Date:  2005-10-01       Impact factor: 3.857

Review 3.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

4.  Around the WORLD backward: an algorithm for scoring the MMSE WORLD item.

Authors:  L A Beckett; R S Wilson; D A Bennett; M C Morris
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

5.  Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ.

Authors:  Ping Yan; Xiaoyan Hu; Haowei Song; Kejie Yin; Randall J Bateman; John R Cirrito; Qingli Xiao; Fong F Hsu; John W Turk; Jan Xu; Chung Y Hsu; David M Holtzman; Jin-Moo Lee
Journal:  J Biol Chem       Date:  2006-06-20       Impact factor: 5.157

Review 6.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

7.  Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment.

Authors:  Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

8.  Degeneration of beta-amyloid-associated cholinergic structures in transgenic APP SW mice.

Authors:  Hans-Joachim Lüth; Jenny Apelt; Amadi O Ihunwo; Thomas Arendt; Reinhard Schliebs
Journal:  Brain Res       Date:  2003-07-04       Impact factor: 3.252

9.  Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.

Authors:  Stefan Lorenzl; Katharina Buerger; Harald Hampel; M Flint Beal
Journal:  Int Psychogeriatr       Date:  2007-08-15       Impact factor: 3.878

Review 10.  Neuroinflammation in plaque and vascular beta-amyloid disorders: clinical and therapeutic implications.

Authors:  Piet Eikelenboom; Rob Veerhuis; Atoosa Familian; Jeroen J M Hoozemans; Willem A van Gool; Annemieke J M Rozemuller
Journal:  Neurodegener Dis       Date:  2008-03-06       Impact factor: 2.977

View more
  56 in total

Review 1.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

Review 2.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

Review 3.  Casting a net on dendritic spines: the extracellular matrix and its receptors.

Authors:  Lorraine E Dansie; Iryna M Ethell
Journal:  Dev Neurobiol       Date:  2011-11       Impact factor: 3.964

Review 4.  The role of inflammatory processes in Alzheimer's disease.

Authors:  G Joseph Broussard; Jennifer Mytar; Rung-chi Li; Gloria J Klapstein
Journal:  Inflammopharmacology       Date:  2012-04-26       Impact factor: 4.473

5.  Study on Mechanism of Ginkgo biloba L. Leaves for the Treatment of Neurodegenerative Diseases Based on Network Pharmacology.

Authors:  Jing Wang; Xialin Chen; Weirong Bai; Zhenzhong Wang; Wei Xiao; Jingbo Zhu
Journal:  Neurochem Res       Date:  2021-05-14       Impact factor: 3.996

6.  An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines.

Authors:  I Dafnis; A K Tzinia; E C Tsilibary; V I Zannis; A Chroni
Journal:  Neuroscience       Date:  2012-03-14       Impact factor: 3.590

7.  The role of progestogens in regulating matrix metalloproteinase activity in macrophages and microglial cells.

Authors:  Juliana Hwang-Levine; Frank Z Stanczyk; Howard N Hodis
Journal:  Neurochem Res       Date:  2011-05-27       Impact factor: 3.996

8.  Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Authors:  Sylvia E Perez; Bin He; Muhammad Nadeem; Joanne Wuu; Stephen W Scheff; Eric E Abrahamson; Milos D Ikonomovic; Elliott J Mufson
Journal:  Biol Psychiatry       Date:  2014-01-11       Impact factor: 13.382

9.  Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease.

Authors:  Elliott J Mufson; Bin He; Muhammad Nadeem; Sylvia E Perez; Scott E Counts; Sue Leurgans; Jason Fritz; James Lah; Stephen D Ginsberg; Joanne Wuu; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

10.  Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease.

Authors:  Elliott J Mufson; Joanne Wuu; Scott E Counts; Anders Nykjaer
Journal:  Neurosci Lett       Date:  2010-01-18       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.